|
1
|
Tu KN, Lie JD, Wan CKV, Cameron M, Austel
AG, Nguyen JK, Van K and Hyun D: Osteoporosis: A review of
treatment options. P T. 43:92–104. 2018.PubMed/NCBI
|
|
2
|
Genant HK, Cooper C, Poor G, Reid I,
Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour
JP, et al: Interim report and recommendations of the World Health
Organization task-force for osteoporosis. Osteoporosis Int.
10:259–264. 1999.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Noh JY, Yang Y and Jung H: Molecular
mechanisms and emerging therapeutics for osteoporosis. Int J Mol
Sci. 21(7623)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wright NC, Looker AC, Saag KG, Curtis JR,
Delzell ES, Randall S and Dawson-Hughes B: The recent prevalence of
osteoporosis and low bone mass in the United States based on bone
mineral density at the femoral neck or lumbar spine. J Bone Miner
Res. 29:2520–2526. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Langdahl BL: Overview of treatment
approaches to osteoporosis. Br J Pharmacol. 178:1891–1906.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Burge R, Dawson-Hughes B, Solomon DH, Wong
JB, King A and Tosteson A: Incidence and economic burden of
osteoporosis-related fractures in the United States, 2005-2025. J
Bone Miner Res. 22:465–475. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Langdahl BL and Harsløf T: Medical
treatment of osteoporotic vertebral fractures. Ther Adv
Musculoskelet Dis. 3:17–29. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Camacho PM, Petak SM, Binkley N, Clarke
BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD,
Narula HS, et al: American association of clinical endocrinologists
and American college of endocrinology clinical practice guidelines
for the diagnosis and treatment of postmenopausal
osteoporosis-2016. Endocr Pract. 22 (Suppl 4):S1–S42.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Akkawi I and Zmerly H: Osteoporosis:
Current concepts. Joints. 6:122–127. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
De Martinis M, Sirufo MM and Ginaldi L:
Osteoporosis: Current and emerging therapies targeted to
immunological checkpoints. Curr Med Chem. 27:6356–6372.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Milat F and Ebeling PR: Osteoporosis
treatment: A missed opportunity. Med J Aust. 205:185–190.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cosman F, de Beur SJ, LeBoff MS, Lewiecki
EM, Tanner B, Randall S and Lindsay R: National Osteoporosis
Foundation. Clinician's guide to prevention and treatment of
osteoporosis. Osteoporos Int. 25:2359–2381. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nuti R, Brandi ML, Checchia G, Di Munno O,
Dominguez L, Falaschi P, Fiore CE, Iolascon G, Maggi S, Michieli R,
et al: Guidelines for the management of osteoporosis and fragility
fractures. Intern Emerg Med. 14:85–102. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Marshall D, Johnell O and Wedel H:
Meta-analysis of how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ. 312:1254–1259.
1996.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Szulc P and Delmas PD: Biochemical markers
of bone turnover: Potential use in the investigation and management
of postmenopausal osteoporosis. Osteoporos Int. 19:1683–1704.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dempster D, Cauley J, Bouxsein M and
Cosman F (eds.): Lessons from bone histomorphometry on the
mechanisms of action of osteoporosis drugs. In: Marcus and
Feldman's Osteoporosis. 5th edition. Academic Press, Cambridge, MA,
USA, pp1835-1863, 2020.
|
|
17
|
Schuiling KD, Robinia K and Nye R:
Osteoporosis update. J Midwifery Womens Health. 56:615–627.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zmuda JM, Sheu YT and Moffett SP: The
search for human osteoporosis genes. J Musculoskelet Neuronal
Interact. 6:3–15. 2006.PubMed/NCBI
|
|
19
|
Sadler C and Huff M: African-American
women: Health beliefs, lifestyle, and osteoporosis. Orthop Nurs.
26:96–101. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kanis JA, Burlet N, Cooper C, Delmas PD,
Reginster JY, Borgstrom F and Rizzoli R: European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO). European guidance for the diagnosis and management of
osteoporosis in postmenopausal women. Osteoporos Int. 19:399–428.
2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kuo TR and Chen CH: Bone biomarker for the
clinical assessment of osteoporosis: Recent developments and future
perspectives. Biomark Res. 5(18)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Qaseem A, Snow V, Shekelle P, Hopkins R
Jr, Forciea MA and Owens DK: Clinical Efficacy Assessment
Subcommittee of the American College of Physicians. Pharmacologic
treatment of low bone density or osteoporosis to prevent fractures:
A clinical practice guideline from the American college of
physicians. Ann Intern Med. 149:404–415. 2008.PubMed/NCBI
|
|
23
|
Wada T, Nakashima T, Hiroshi N and
Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone
disease. Trends Mol Med. 12:17–25. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li H, Xiao Z, Quarles LD and Li W:
Osteoporosis: Mechanism, molecular target and current status on
drug development. Curr Med Chem. 28:1489–1507. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
et al: Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wong BR, Rho J, Arron J, Robinson E,
Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III,
Frankel WN, et al: TRANCE is a novel ligand of the tumor necrosis
factor receptor family that activates c-Jun N-terminal kinase in T
cells. J Biol Chem. 272:25190–25194. 1997.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Park JH, Lee NK and Lee SY: Current
understanding of RANK signaling in osteoclast differentiation and
maturation. Mol Cells. 40:706–713. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu F and Teitelbaum SL: Osteoclasts: New
insights. Bone Res. 1:11–26. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yamashita T, Takahashi N and Udagawa N:
New roles of osteoblasts involved in osteoclast differentiation.
World J Orthop. 3:175–181. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rucci N: Molecular biology of bone
remodelling. Clin Cases Miner Bone Metab. 5:49–56. 2008.PubMed/NCBI
|
|
32
|
Teitelbaum SL: Bone resorption by
osteoclasts. Science. 289:1504–1508. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hienz SA, Paliwal S and Ivanovski S:
Mechanisms of bone resorption in periodontitis. J Immunol Res.
2015(615486)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Das S and Crockett JC: Osteoporosis-a
current view of pharmacological prevention and treatment. Drug Des
Devel Ther. 7:435–448. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Henriksen K, Bollerslev J, Everts V and
Karsdal MA: Osteoclast activity and subtypes as a function of
physiology and pathology-implications for future treatments of
osteoporosis. Endocr Rev. 32:31–63. 2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Arnett T: Regulation of bone cell function
by acid-base balance. Proc Nutr Soc. 62:511–520. 2003.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Blair HC, Zaidi M, Huang CL and Sun L: The
developmental basis of skeletal cell differentiation and the
molecular basis of major skeletal defects. Biol Rev Camb Philos
Soc. 83:401–415. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal
RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and
Marshak DR: Multilineage potential of adult human mesenchymal stem
cells. Science. 284:143–147. 1999.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nakashima K and de Crombrugghe B:
Transcriptional mechanisms in osteoblast differentiation and bone
formation. Trends Genet. 19:458–466. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Brighton CT and Hunt RM: Histochemical
localization of calcium in the fracture callus with potassium
pyroantimonate. Possible role of chondrocyte mitochondrial calcium
in callus calcification. J Bone Joint Surg Am. 68:703–715.
1986.PubMed/NCBI
|
|
41
|
de Crombrugghe B, Lefebvre V and Nakashima
K: Regulatory mechanisms in the pathways of cartilage and bone
formation. Curr Opin Cell Biol. 13:721–727. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Brighton CT and Hunt RM: Early
histological and ultrastructural changes in medullary fracture
callus. J Bone Joint Surg Am. 73:832–847. 1991.PubMed/NCBI
|
|
43
|
Soltanoff CS, Yang S, Chen W and Li YP:
Signaling networks that control the lineage commitment and
differentiation of bone cells. Crit Rev Eukaryot Gene Expr 19,
2009.
|
|
44
|
Chau JF, Leong WF and Li B: Signaling
pathways governing osteoblast proliferation, differentiation and
function. Histol Histopathol. 24:1593–1606. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Meyer MB, Benkusky NA and Pike JW: The
RUNX2 cistrome in osteoblasts: Characterization, down-regulation
following differentiation, and relationship to gene expression. J
Biol Chem. 289:16016–16031. 2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lin GL and Hankenson KD: Integration of
BMP, Wnt, and notch signaling pathways in osteoblast
differentiation. J Cell Biochem. 112:3491–3501. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Burch J, Rice S, Yang H, Neilson A, Stirk
L, Francis R, Holloway P, Selby P and Craig D: Systematic review of
the use of bone turnover markers for monitoring the response to
osteoporosis treatment: The secondary prevention of fractures, and
primary prevention of fractures in high-risk groups. Health Technol
Assess. 18:1–180. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mori G, D'Amelio P, Faccio R and Brunetti
G: The interplay between the bone and the immune system. Clin Dev
Immunol. 2013(720504)2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lacey DL, Boyle WJ, Simonet WS, Kostenuik
PJ, Dougall WC, Sullivan JK, San Martin J and Dansey R: Bench to
bedside: Elucidation of the OPG-RANK-RANKL pathway and the
development of denosumab. Nat Rev Drug Discov. 11:401–419.
2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Noble BS: The osteocyte lineage. Arch
Biochem Biophys. 473:106–111. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Klein-Nulend J, Nijweide PJ and Burger EH:
Osteocyte and bone structure. Curr Osteoporos Rep. 1:5–10.
2003.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Rochefort GY: The osteocyte as a
therapeutic target in the treatment of osteoporosis. Ther Adv
Musculoskelet Dis. 6:79–91. 2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Bonewald LF: The amazing osteocyte. J Bone
Miner Res. 26:229–238. 2011.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Nakashima T, Hayashi M, Fukunaga T, Kurata
K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, et
al: Evidence for osteocyte regulation of bone homeostasis through
RANKL expression. Nat Med. 17:1231–1234. 2011.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Goldring SR: The osteocyte: Key player in
regulating bone turnover. RMD Open. 1 (Suppl
1)(e000049)2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Moriishi T, Fukuyama R, Ito M, Miyazaki T,
Maeno T, Kawai Y, Komori H and Komori T: Osteocyte network; a
negative regulatory system for bone mass augmented by the induction
of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS
One. 7(e40143)2012.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Kramer I, Halleux C, Keller H, Pegurri M,
Gooi JH, Weber PB, Feng JQ, Bonewald LF and Kneissel M: Osteocyte
Wnt/beta-catenin signaling is required for normal bone homeostasis.
Mol Cell Biol. 30:3071–3085. 2010.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Bellido T: Osteocyte apoptosis induces
bone resorption and impairs the skeletal response to
weightlessness. IBMS BoneKEy. 4(252)2007.
|
|
59
|
Chamoux E, Houde N, L'eriger K and Roux S:
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting
the TRAIL pathway. J Cell Physiol. 216:536–542. 2008.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Yen ML, Hsu PN, Liao HJ, Lee BH and Tsai
HF: TRAF-6 dependent signaling pathway is essential for TNF-related
apoptosis-inducing ligand (TRAIL) induces osteoclast
differentiation. PLoS One. 7(e38048)2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Bikle DD: Vitamin D metabolism, mechanism
of action, and clinical applications. Chem Biol. 21:319–329.
2014.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Norman AW: From vitamin D to hormone D:
Fundamentals of the vitamin D endocrine system essential for good
health. Am J Clin Nutr. 88:491S–499S. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Valero Zanuy M and Hawkins Carranza F:
Metabolism, endogenous and exogenous sources of vitamin D. Rev Esp
Enferm Metab Oseas. 16:63–70. 2007.
|
|
64
|
Silva MC and Furlanetto TW: Intestinal
absorption of vitamin D: A systematic review. Nutr Rev. 76:60–76.
2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Compston JE, Merrett AL, Hammett FG and
Magill P: Comparison of the appearance of radiolabelled vitamin D3
and 25-hydroxy-vitamin D3 in the chylomicron fraction of plasma
after oral administration in man. Clin Sci (Lond). 60:241–243.
1981.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Gil A, Plaza-Diaz J and Mesa MD: Vitamin
D: Classic and novel actions. Ann Nutr Metab. 72:87–95.
2018.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Naveh-Many T, Marx R, Keshet E, Pike JW
and Silver J: Regulation of 1, 25-dihydroxyvitamin D3 receptor gene
expression by 1, 25-dihydroxyvitamin D3 in the parathyroid in vivo.
J Clin Invest. 86:1968–1975. 1990.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Glendenning P, Ratajczak T, Dick IM and
Prince RL: Calcitriol upregulates expression and activity of the 1b
isoform of the plasma membrane calcium pump in immortalized distal
kidney tubular cells. Arch Biochem Biophys. 380:126–132.
2000.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Kuchuk NO, van Schoor NM, Pluijm SM,
Chines A and Lips P: Vitamin D status, parathyroid function, bone
turnover, and BMD in postmenopausal women with osteoporosis: Global
perspective. J Bone Miner Res. 24:693–701. 2009.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Harada S, Mizoguchi T, Kobayashi Y,
Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H,
Udagawa N, et al: Daily administration of eldecalcitol (ED-71), an
active vitamin D analog, increases bone mineral density by
suppressing RANKL expression in mouse trabecular bone. J Bone Miner
Res. 27:461–473. 2012.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Takeda S, Yoshizawa T, Nagai Y, Yamato H,
Fukumoto S, Sekine K, Kato S, Matsumoto T and Fujita T: Stimulation
of osteoclast formation by 1, 25-dihydroxyvitamin D requires its
binding to vitamin D receptor (VDR) in osteoblastic cells: studies
using VDR knockout mice. Endocrinology. 140:1005–1008.
1999.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Christakos S, Dhawan P, Verstuyf A,
Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular
mechanism of action, and pleiotropic effects. Physiol Rev.
96:365–408. 2016.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Kim S, Yamazaki M, Zella LA, Shevde NK and
Pike JW: Activation of receptor activator of NF-kappaB ligand gene
expression by 1, 25-dihydroxyvitamin D3 is mediated through
multiple long-range enhancers. Mol Cell Biol. 26:6469–6486.
2006.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ukon Y, Makino T, Kodama J, Tsukazaki H,
Tateiwa D, Yoshikawa H and Kaito T: Molecular-based treatment
strategies for osteoporosis: A literature review. Int J Mol Sci.
20(2557)2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Watts NB, Bilezikian JP, Camacho PM,
Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM,
McClung MR, Pollack RP, et al: American association of clinical
endocrinologists medical guidelines for clinical practice for the
diagnosis and treatment of postmenopausal osteoporosis. Endocr
Pract. 16 (Suppl 3):S1–S37. 2010.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kim SY, Zhang M and Bockman R: Bone
mineral density response from teriparatide in patients with
osteoporosis. HSS J. 13:171–177. 2017.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Estell EG and Rosen CJ: Emerging insights
into the comparative effectiveness of anabolic therapies for
osteoporosis. Nat Rev Endocrinol. 17:31–46. 2021.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Pavone V, Testa G, Giardina SMC, Vescio A,
Restivo DA and Sessa G: Pharmacological therapy of osteoporosis: A
systematic current review of literature. Front Pharmacol.
8(803)2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
North American Menopause Societ.
Management of osteoporosis in postmenopausal women: 2006 position
statement of The North American menopause society. Menopause.
13:340–367; quiz 368-9. 2006.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Drake MT, Clarke BL and Khosla S:
Bisphosphonates: mechanism of action and role in clinical practice.
Mayo Clin Proc. 83:1032–1045. 2008.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Colucci S, Minielli V, Zambonin G, Cirulli
N, Mori G, Serra M, Patella V, Zambonin Zallone A and Grano M:
Alendronate reduces adhesion of human osteoclast-like cells to bone
and bone protein-coated surfaces. Calcif Tissue Int. 63:230–235.
1998.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Sato M, Grasser W, Endo N, Akins R,
Simmons H, Thompson DD, Golub E and Rodan GA: Bisphosphonate
action. Alendronate localization in rat bone and effects on
osteoclast ultrastructure. J Clin Invest. 88:2095–2105.
1991.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Papapoulos SE: Bisphosphonates: How do
they work? Best Pract Res Clin Endocrinol Metab. 22:831–847.
2008.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Russell RG: Bisphosphonates: The first 40
years. Bone. 49:2–19. 2011.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Barnsley J, Buckland G, Chan PE, Ong A,
Ramos AS, Baxter M, Laskou F, Dennison EM, Cooper C and Patel HP:
Pathophysiology and treatment of osteoporosis: Challenges for
clinical practice in older people. Aging Clin Exp Res. 33:759–773.
2021.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Garg MK and Kharb S: Dual energy X-ray
absorptiometry: Pitfalls in measurement and interpretation of bone
mineral density. Indian J Endocrinol Metab. 17:203–210.
2013.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Rogers MJ: From molds and macrophages to
mevalonate: A decade of progress in understanding the molecular
mode of action of bisphosphonates. Calcif Tissue Int. 75:451–461.
2004.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Russell RG: Bisphosphonates: Mode of
action and pharmacology. Pediatrics. 119 (Suppl 2):S150–S162.
2007.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Dunford JE: Molecular targets of the
nitrogen containing bisphosphonates: The molecular pharmacology of
prenyl synthase inhibition. Curr Pharm Des. 16:2961–2969.
2010.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kanis JA, Cooper C, Rizzoli R and
Reginster JY: Scientific Advisory Board of the European Society for
Clinical and Economic Aspects of Osteoporosis (ESCEO) and the
Committees of Scientific Advisors and National Societies of the
International Osteoporosis Foundation (IOF). European guidance for
the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos Int. 30:3–44. 2019.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Simon JA: Are all bisphosphonates the
same? Potential reasons for clinical differences: A perspective. J
Womens Health (Larchmt). 19:719–727. 2010.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Qaseem A, Forciea MA, McLean RM and
Denberg TD: Clinical Guidelines Committee of the American College
of Physicians. Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey
LL, et al: Treatment of low bone density or osteoporosis to prevent
fractures in men and women: A clinical practice guideline update
from the American College of Physicians. Ann Intern Med.
166:818–839. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Nelson HD, Haney EM, Dana T, Bougatsos C
and Chou R: Screening for osteoporosis: An update for the US
preventive services task force. Ann Intern Med. 153:99–111.
2010.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Park-Wyllie LY, Mamdani MM, Juurlink DN,
Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ and Laupacis
A: Bisphosphonate use and the risk of subtrochanteric or femoral
shaft fractures in older women. JAMA. 305:783–789. 2011.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Rossini M, Adami S, Bertoldo F, Diacinti
D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella
G, et al: Guidelines for the diagnosis, prevention and management
of osteoporosis. Reumatismo. 68:1–39. 2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Pazianas M and Abrahamsen B: Osteoporosis
treatment: Bisphosphonates reign to continue for a few more years,
at least? Ann N Y Acad Sci. 1376:5–13. 2016.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Lorentzon M: Treating osteoporosis to
prevent fractures: Current concepts and future developments. J
Intern Med. 285:381–394. 2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Tsourdi E, Langdahl B, Cohen-Solal M,
Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B,
Ralston SH, Eastell R and Zillikens MC: Discontinuation of
denosumab therapy for osteoporosis: A systematic review and
position statement by ECTS. Bone. 105:11–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka
H, Yoneda T, Ohira T, Okubo N, Genant HK and van der Heijde D:
Effect of denosumab on Japanese patients with rheumatoid arthritis:
A dose-response study of AMG 162 (Denosumab) in patients with
RheumatoId arthritis on methotrexate to Validate inhibitory effect
on bone Erosion (DRIVE)-a 12-month, multicentre, randomised,
double-blind, placebo-controlled, phase II clinical trial. Ann
Rheum Dis. 75:983–990. 2016.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Bone HG, Wagman RB, Brandi ML, Brown JP,
Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A,
Kendler DL, Lippuner K, et al: 10 years of denosumab treatment in
postmenopausal women with osteoporosis: Results from the phase 3
randomised FREEDOM trial and open-label extension. Lancet Diabetes
Endocrinol. 5:513–523. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Tabatabaei-Malazy O, Salari P, Khashayar P
and Larijani B: New horizons in treatment of osteoporosis. DARU.
25(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Bonani M, Frey D, de Rougemont O, Mueller
NJ, Mueller TF, Graf N and Wüthrich RP: Infections in de novo
kidney transplant recipients treated with the RANKL inhibitor
denosumab. Transplantation. 101:2139–2145. 2017.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Cummings SR, Ferrari S, Eastell R,
Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I,
Wang AT and Brown JP: Vertebral fractures after discontinuation of
denosumab: A post hoc analysis of the randomized placebo-controlled
FREEDOM trial and its extension. J Bone Miner Res. 33:190–198.
2018.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Krum SA and Brown M: Unraveling estrogen
action in osteoporosis. Cell Cycle. 7:1348–1352. 2008.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Kanis JA, McCloskey EV, Johansson H,
Cooper C, Rizzoli R and Reginster JY: Scientific Advisory Board of
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) and the Committee of
Scientific Advisors of the International Osteoporosis Foundation
(IOF). European guidance for the diagnosis and management of
osteoporosis in postmenopausal women. Osteoporos Int. 24:23–57.
2013.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Lobo RA, Pickar JH, Stevenson JC, Mack WJ
and Hodis HN: Back to the future: Hormone replacement therapy as
part of a prevention strategy for women at the onset of menopause.
Atherosclerosis. 254:282–290. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Cartwright B, Robinson J, Seed PT,
Fogelman I and Rymer J: Hormone replacement therapy versus the
combined oral contraceptive pill in premature ovarian failure: A
randomized controlled trial of the effects on bone mineral density.
J Clin Endocrinol Metab. 101:3497–3505. 2016.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Rossouw JE, Anderson GL, Prentice RL,
LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA,
Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: Principal results from
the Women's Health Initiative randomized controlled trial. JAMA.
288:321–333. 2002.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Maximov PY, Lee TM and Jordan VC: The
discovery and development of selective estrogen receptor modulators
(SERMs) for clinical practice. Curr Clin Pharmacol. 8:135–155.
2013.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Siddiqui JA and Partridge NC:
Physiological bone remodeling: Systemic regulation and growth
factor involvement. Physiology (Bethesda). 31:233–245.
2016.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Gooi JH, Pompolo S, Karsdal MA, Kulkarni
NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT,
et al: Calcitonin impairs the anabolic effect of PTH in young rats
and stimulates expression of sclerostin by osteocytes. Bone.
46:1486–1497. 2010.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Keller J, Catala-Lehnen P, Huebner AK,
Jeschke A, Heckt T, Lueth A, Krause M, Koehne T, Albers J, Schulze
J, et al: Calcitonin controls bone formation by inhibiting the
release of sphingosine 1-phosphate from osteoclasts. Nat Commun.
5(5215)2014.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Bandeira L, Lewiecki EM and Bilezikian JP:
Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in
the treatment of osteoporosis. Expert Opin Drug Metab Toxicol.
12:681–689. 2016.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Drake MT, Clarke BL, Oursler MJ and Khosla
S: Cathepsin K inhibitors for osteoporosis: Biology, potential
clinical utility, and lessons learned. Endocr Rev. 38:325–350.
2017.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Dai R, Wu Z, Chu HY, Lu J, Lyu A, Liu J
and Zhang G: Cathepsin K: The action in and beyond bone. Front Cell
Dev Biol. 8(433)2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Takito J, Inoue S and Nakamura M: The
sealing zone in osteoclasts: A self-organized structure on the
bone. Int J Mol Sci. 19(984)2018.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Fonović M and Turk B: Cysteine cathepsins
and extracellular matrix degradation. Biochim Biophys Acta.
1840:2560–2570. 2014.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Mullard A: Merck & Co. drops
osteoporosis drug odanacatib. Nat Rev Drug Discov.
15(669)2016.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Brömme D and Lecaille F: Cathepsin K
inhibitors for osteoporosis and potential off-target effects.
Expert Opin Investig Drugs. 18:585–600. 2009.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Eastell R, Nagase S, Ohyama M, Small M,
Sawyer J, Boonen S, Spector T, Kuwayama T and Deacon S: Safety and
efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal
osteoporosis: The OCEAN study. J Bone Miner Res. 26:1303–1312.
2011.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Stoch SA, Zajic S, Stone JA, Miller DL,
van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, et
al: Odanacatib, a selective cathepsin K inhibitor to treat
osteoporosis: safety, tolerability, pharmacokinetics and
pharmacodynamics-results from single oral dose studies in healthy
volunteers. Br J Clin Pharmacol. 75:1240–1254. 2013.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Khan B, Ahmed Z and Ahmad W: A novel
missense mutation in cathepsin K (CTSK) gene in a consanguineous
Pakistani family with pycnodysostosis. J Investig Med. 58:720–724.
2010.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Iñiguez-Ariza NM and Clarke BL: Bone
biology, signaling pathways, and therapeutic targets for
osteoporosis. Maturitas. 82:245–255. 2015.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Chapurlat RD: Odanacatib: A review of its
potential in the management of osteoporosis in postmenopausal
women. Ther Adv Musculoskelet Dis. 7:103–109. 2015.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Marie PJ: The calcium-sensing receptor in
bone cells: A potential therapeutic target in osteoporosis. Bone.
46:571–576. 2010.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Spector TD, Calomme MR, Anderson SH,
Clement G, Bevan L, Demeester N, Swaminathan R, Jugdaohsingh R,
Berghe DA and Powell JJ: Choline-stabilized orthosilicic acid
supplementation as an adjunct to calcium/vitamin D3 stimulates
markers of bone formation in osteopenic females: A randomized,
placebo-controlled trial. BMC Musculoskelet Disord.
9(85)2008.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Hamdy NA: Strontium ranelate improves bone
microarchitecture in osteoporosis. Rheumatology (Oxford). 48 (Suppl
4):iv9–iv13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Pilmane M, Salma-Ancane K, Loca D, Locs J
and Berzina-Cimdina L: Strontium and strontium ranelate: Historical
review of some of their functions. Mater Sci Eng C Mater Biol Appl.
78:1222–1230. 2017.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Delany AM, Amling M, Priemel M, Howe C,
Baron R and Canalis E: Osteopenia and decreased bone formation in
osteonectin-deficient mice. J Clin Invest. 105:915–923.
2000.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Kanis JA, Johansson H, Oden A and
McCloskey EV: A meta-analysis of the effect of strontium ranelate
on the risk of vertebral and non-vertebral fracture in
postmenopausal osteoporosis and the interaction with FRAX®.
Osteoporos Int. 22:2347–2355. 2011.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Bolland MJ and Grey A: A comparison of
adverse event and fracture efficacy data for strontium ranelate in
regulatory documents and the publication record. BMJ Open.
4(e005787)2014.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Mi B, Xiong W, Xu N, Guan H, Fang Z, Liao
H, Zhang Y, Gao B, Xiao X, Fu J and Li F: Strontium-loaded titania
nanotube arrays repress osteoclast differentiation through multiple
signalling pathways: In vitro and in vivo studies. Sci Rep.
7(2328)2017.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Gupta S, Termini JM, Kanagavelu S and
Stone GW: Design of vaccine adjuvants incorporating TNF superfamily
ligands and TNF superfamily molecular mimics. Immunol Res.
57:303–310. 2013.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Liu C, Walter TS, Huang P, Zhang S, Zhu X,
Wu Y, Wedderburn LR, Tang P, Owens RJ, Stuart DI, et al: Structural
and functional insights of RANKL-RANK interaction and signaling. J
Immunol. 184:6910–6919. 2010.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Ko YJ, Sohn HM, Jang Y, Park M, Kim B, Kim
B, Park JI, Hyun H, Jeong B, Hong C and Lim W: A novel modified
RANKL variant can prevent osteoporosis by acting as a vaccine and
an inhibitor. Clin Transl Med. 11(e368)2021.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Jang Y, Sohn HM, Ko YJ, Hyun H and Lim W:
Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant
RANKL. Int J Mol Sci. 22(434)2021.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Liu C, Zhao Y, He W, Wang W, Chen Y, Zhang
S, Ma Y, Gohda J, Ishida T, Walter TS, et al: A RANKL mutant used
as an inter-species vaccine for efficient immunotherapy of
osteoporosis. Sci Rep. 5(14150)2015.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Wu T, Li F, Sha X, Li F, Zhang B, Ma W,
Liu M, Yang W, Li H and Tao H: A novel recombinant RANKL vaccine
prepared by incorporation of an unnatural amino acid into RANKL and
its preventive effect in a murine model of collagen-induced
arthritis. Int Immunopharmacol. 64:326–332. 2018.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Ling L, Hu HL, Liu KY, Ram YI, Gao JL and
Cao YM: Long noncoding RNA MIRG induces osteoclastogenesis and bone
resorption in osteoporosis through negative regulation of miR-1897.
Eur Rev Med Pharmacol Sci. 23:10195–10203. 2019.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Wu QY, Li X, Miao ZN, Ye JX, Wang B, Zhang
F, Xu RS, Jiang DL, Zhao MD and Yuan FL: Long Non-coding RNAs: A
new regulatory code for osteoporosis. Front Endocrinol (Lausanne).
9(587)2018.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Zhu J, Yu W, Wang Y, Xia K, Huang Y, Xu A,
Chen Q, Liu B, Tao H, Li F and Liang C: lncRNAs: function and
mechanism in cartilage development, degeneration, and regeneration.
Stem Cell Res Ther. 10(344)2019.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Wijnen WJ, Pinto YM and Creemers EE: The
therapeutic potential of miRNAs in cardiac fibrosis: Where do we
stand? J Cardiovasc Transl Res. 6:899–908. 2013.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Mandourah AY, Ranganath L, Barraclough R,
Vinjamuri S, Hof RV, Hamill S, Czanner G, Dera AA, Wang D and
Barraclough DL: Circulating microRNAs as potential diagnostic
biomarkers for osteoporosis. Sci Rep. 8(8421)2018.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Rachner TD, Hofbauer LC, Göbel A and
Tsourdi E: Novel therapies in osteoporosis: PTH-related peptide
analogs and inhibitors of sclerostin. J Mol Endocrinol.
62:R145–R154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Borba VZ and Mañas NC: The use of PTH in
the treatment of osteoporosis. Arq Bras Endocrinol Metabol.
54:213–219. 2010.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Silva BC and Bilezikian JP: Parathyroid
hormone: Anabolic and catabolic actions on the skeleton. Curr Opin
Pharmacol. 22:41–50. 2015.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Gardella T: Interactions of PTH with
Receptors and Signaling. The Parathyroids: Basic and Clinical
Concepts. Third ed. Elsevier Inc: 65-80, 2015.
|
|
148
|
Datta NS and Abou-Samra AB: PTH and PTHrP
signaling in osteoblasts. Cell Signal. 21(8):1245–1254.
2009.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Migliaccio S, Brama M and Malavolta N:
Management of glucocorticoids-induced osteoporosis: Role of
teriparatide. Ther Clin Risk Manag. 5:305–310. 2009.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Recker RR, Marin F, Ish-Shalom S, Möricke
R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J,
Sanz B, et al: Comparative effects of teriparatide and strontium
ranelate on bone biopsies and biochemical markers of bone turnover
in postmenopausal women with osteoporosis. J Bone Miner Res.
24:1358–1368. 2009.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Rubin MR and Bilezikian JP: New anabolic
therapies in osteoporosis. Endocrinol Metab Clin North Am.
32:285–307. 2003.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Glover SJ, Eastell R, McCloskey EV, Rogers
A, Garnero P, Lowery J, Belleli R, Wright TM and John MR: Rapid and
robust response of biochemical markers of bone formation to
teriparatide therapy. Bone. 45:1053–1058. 2009.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Cosman F: Abaloparatide: A new anabolic
therapy on the horizon. Bonekey Rep. 4(661)2015.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Neer RM, Arnaud CD, Zanchetta JR, Prince
R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S,
Genant HK, et al: Effect of parathyroid hormone (1-34) on fractures
and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 344:1434–1441. 2001.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Fukumoto S and Matsumoto T: Recent
advances in the management of osteoporosis. F1000Research.
6(625)2017.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Cheloha RW, Gellman SH, Vilardaga JP and
Gardella TJ: PTH receptor-1 signalling-mechanistic insights and
therapeutic prospects. Nat Rev Endocrinol. 11:712–724.
2015.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Hattersley G, Dean T, Corbin BA, Bahar H
and Gardella TJ: Binding selectivity of abaloparatide for
PTH-type-1-receptor conformations and effects on downstream
signaling. Endocrinology. 157:141–149. 2016.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Boyce EG, Mai Y and Pham C: Abaloparatide:
Review of a next-generation parathyroid hormone agonist. Ann
Pharmacother. 52:462–472. 2018.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Gensure RC, Gardella TJ and Jüppner H:
Parathyroid hormone and parathyroid hormone-related peptide, and
their receptors. Biochem Biophys Res Commun. 328:666–678.
2005.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Wysolmerski JJ: Parathyroid
hormone-related protein: An update. J Clin Endocrinol Metab.
97:2947–2956. 2012.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Iolascon G, Moretti A, Toro G, Gimigliano
F, Liguori S and Paoletta M: Pharmacological therapy of
osteoporosis: What's new? Clin Interv Aging. 15:485–491.
2020.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Pietrzyk B, Smertka M and Chudek J:
Sclerostin: Intracellular mechanisms of action and its role in the
pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med.
26:1283–1291. 2017.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Lerner UH and Ohlsson C: The WNT system:
background and its role in bone. J Intern Med. 277:630–649.
2015.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang
J, Harris SE and Wu D: Sclerostin binds to LRP5/6 and antagonizes
canonical Wnt signaling. J Biol Chem. 280:19883–19887.
2005.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Cosman F, Crittenden DB, Adachi JD,
Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki
EM, Miyauchi A, et al: Romosozumab treatment in postmenopausal
women with osteoporosis. N Engl J Med. 375:1532–1543.
2016.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Canalis E: Management of endocrine
disease: Novel anabolic treatments for osteoporosis. Eur J
Endocrinol. 178:R33–R44. 2018.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Black DM, Greenspan SL, Ensrud KE, Palermo
L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP and
Rosen CJ: PaTH Study Investigators. The effects of parathyroid
hormone and alendronate alone or in combination in postmenopausal
osteoporosis. N Engl J Med. 349:1207–1215. 2003.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Lou S, Lv H, Yin P, Li Z, Tang P and Wang
Y: Combination therapy with parathyroid hormone analogs and
antiresorptive agents for osteoporosis: A systematic review and
meta-analysis of randomized controlled trials. Osteoporos Int.
30:59–70. 2019.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Leder BZ, Tsai JN, Uihlein AV,
Burnett-Bowie SA, Zhu Y, Foley K, Lee H and Neer RM: Two years of
Denosumab and teriparatide administration in postmenopausal women
with osteoporosis (The DATA Extension Study): A randomized
controlled trial. J Clin Endocrinol Metab. 99:1694–1700.
2014.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Kitaguchi K, Kashii M, Ebina K, Kaito T,
Okada R, Makino T, Noguchi T, Ishimoto T, Nakano T and Yoshikawa H:
Effects of single or combination therapy of teriparatide and
anti-RANKL monoclonal antibody on bone defect regeneration in mice.
Bone. 106:1–10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Saag KG, Petersen J, Brandi ML, Karaplis
AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD and Grauer
A: Romosozumab or alendronate for fracture prevention in women with
osteoporosis. N Engl J Med. 377:1417–1427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Langdahl BL, Libanati C, Crittenden DB,
Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K,
Finkelstein JS, Genant HK, et al: Romosozumab (sclerostin
monoclonal antibody) versus teriparatide in postmenopausal women
with osteoporosis transitioning from oral bisphosphonate therapy: A
randomised, open-label, phase 3 trial. Lancet. 390:1585–1594.
2017.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Bone HG, Cosman F, Miller PD, Williams GC,
Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S,
Rizzoli R, et al: ACTIVExtend: 24 months of alendronate after 18
months of abaloparatide or placebo for postmenopausal osteoporosis.
J Clin Endocrinol Metab. 103:2949–2957. 2018.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Leder BZ, Tsai JN, Uihlein AV, Wallace PM,
Lee H, Neer RM and Burnett-Bowie SA: Denosumab and teriparatide
transitions in postmenopausal osteoporosis (the DATA-Switch study):
Extension of a randomised controlled trial. Lancet. 386:1147–1155.
2015.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Bell NH and Johnson RH: Bisphosphonates in
the treatment of osteoporosis. Endocrine. 6:203–206.
1997.PubMed/NCBI View Article : Google Scholar
|
